

Your link to patient support

Please see accompanying full Prescribing Information and Patient Information for DANYELZA® (naxitamab-gqgk) 40 mg/10 mL Injection including Boxed Warning on serious infusion-related reactions and neurotoxicity. The Prescribing Information is also available at Labeling.ymabs.com/danyelza

Y-mAbs Connect case managers can provide access and reimbursement support for patients prescribed a Y-mAbs medication.

The dedicated team can:

- Conduct a benefits investigation to help understand your patient's insurance coverage for DANYELZA
- Provide prior authorization (PA) and appeals information
- Determine your patient's eligibility for Y-mAbs Connect financial support programs
- Provide information on third-party programs that may be able to provide financial or logistical support for your patient
- Address logistical questions around distribution and delivery of DANYELZA



Y-mAbs Connect can provide the following insurance support:

Benefits Investigation

Case managers can conduct a benefits investigation to help understand your patient's insurance coverage and out-of-pocket costs for DANYELZA.

PA Support

Case managers can work with your patient's insurer to determine PA requirements and track progress of PA outcome.

Appeals Support

If your patient's PA is denied, case managers can work with your patient's insurer to determine the requirements for an appeal and track progress of appeals submission.

Get started by enrolling your patient in Y-mAbs Connect.



To download the enrollment form, go to www.ymabsconnect.com.



Please see accompanying full Prescribing Information and Patient Information for DANYELZA® (naxitamab-gqgk) 40 mg/10 mL Injection including Boxed Warning on serious infusion-related reactions and neurotoxicity. The Prescribing Information is also available at labeling.ymabs.com/danyelza

If your patient is uninsured or needs help affording DANYELZA, speak to a Y-mAbs Connect case manager to see if they qualify for one of the financial support programs below:

Y-mAbs Connect Co-pay Program

If your patient has commercial or private insurance, they may be eligible* for the Co-pay Program. This program could help reduce out-of-pocket costs of DANYELZA to \$0 for eligible patients.

*Patients must be enrolled in Y-mAbs Connect for this program. Eligibility criteria include but are not limited to patients who have commercial or private insurance, are U.S. or U.S. territory residents, and are actively insured at time of treatment. Government- or publicly-insured patients are <u>not</u> eligible. Please visit <u>www.ymabsconnect.com</u> for additional eligibility criteria and terms and conditions.

Note: Y-mAbs Therapeutics, Inc. reserves the right at any time, and without notice, to modify or discontinue this program and any support provided to the patient.

Y-mAbs Connect Patient Assistance Program (PAP)

If your patient is uninsured or rendered underinsured for DANYELZA through their health plan, they may be eligible* for the PAP. This program may be able to provide DANYELZA to eligible patients at no cost.

*Patients must be enrolled in Y-mAbs Connect and must meet certain eligibility criteria for this program. Please visit www.ymabsconnect.com for eligibility criteria.

Note: Y-mAbs Therapeutics, Inc. reserves the right at any time, and without notice, to modify or discontinue this program and any support provided to the patient.

Y-mAbs Connect case managers can provide information about other available third-party organizations that may provide:

- Financial support
- Travel support such as lodging and travel costs to infusion site

Note: Third-party organizations are not associated with Y-mAbs Therapeutics, Inc.; specific details and eligibility requirements may vary by organization.

For any questions on the information above, speak with a Y-mAbs Connect case manager at 1-833-33YMABS (1-833-339-6227), option (2), Monday through Friday, 8AM to 8PM ET.



Please see accompanying full Prescribing Information and Patient Information for DANYELZA® (naxitamab-gqgk) 40 mg/10 mL Injection including Boxed Warning on serious infusion-related reactions and neurotoxicity. The Prescribing Information is also available at labeling.ymabs.com/danyelza

Steps to getting your patient started on DANYELZA:

- Complete the enrollment form with your patient or their caregiver and return it to Y-mAbs Connect
- Verify your patient's coverage for DANYELZA*
- Receive a patient-unique ID from Y-mAbs Connect[†]
- Place an order for DANYELZA through a participating specialty distributor (SD)
- 5 Receive shipment at the infusion site

*Y-mAbs Connect case managers can provide access and reimbursement support for qualified patients prescribed DANYELZA. †Patient-unique ID is required to order DANYELZA through the SD.

Enroll your patient in Y-mAbs Connect prior to ordering DANYELZA



To download the enrollment form, go to www.ymabsconnect.com.

Note: Completing and returning an enrollment form does not require a commitment to prescribe or order DANYELZA.

Product Distribution

DANYELZA is distributed to infusion sites through a limited SD network.



Please download the How to Order resource at www.ymabsconnect.com for more information.

Have questions?

VISIT <u>www.ymabsconnect.com</u> or call 1-833-33YMABS (1-833-339-6227), option (2), Monday through Friday, 8AM to 8PM ET. We are closed on weekends and major holidays.







